Abivax Repurchases $90 Million in Royalty Certificates, Streamlining Capital Structure Ahead of Obefazimod Commercialization
核心洞察
Abivax SA agreed to repurchase all outstanding royalty certificates issued in 2022 for a total of $90 million, split evenly between cash and an equity offering of 403,347 American Depositary Shares.
The transaction eliminates a royalty overhang that had weighed on future commercialization economics for lead candidate obefazimod, currently in Phase 3 trials for ulcerative colitis (搜索).
The company's cash runway remains unchanged into Q4 2027, with €530.4 million in cash and equivalents reported as of December 31, 2025.
Abivax SA, a clinical-stage biotechnology company developing immune-modulating therapies for chronic inflammatory diseases, announced on May 5, 2026, that it has entered into a purchase agreement to repurchase all outstanding royalty certificates issued in September 2022. The total repurchase price of $90 million will be paid through $45 million in cash and $45 million via an interest-free vendor's loan that will be converted into 403,347 American Depositary Shares (ADSs), effectively eliminating a royalty obligation that had been a concern for investors evaluating the company's future commercial prospects.
Didier Blondel, Chief Financial Officer of Abivax, stated: "Strengthening our balance sheet remains a core priority as we continue to reduce legacy obligations. The current market environment presents a compelling opportunity to proactively repurchase these royalty certificates on attractive terms, allowing us to simplify our capital structure and enhance long-term shareholder value."
Transaction Structure and Terms
The royalty certificates were originally issued to a group of institutional investors including TCG Crossover Fund I, L.P., VHCP ABVX Holdings, LLC, Deep Track Biotechnology Master Fund, Ltd., Sofinnova Crossover I SLP, Invus Public Equities, L.P., FPCI BioMedTech, and Santé Holdings Srl. Under the purchase agreement executed on May 4, 2026, these holders agreed to sell all royalty certificates back to the company.
The equity component is structured as a $45 million capital increase through an offering of new ADSs priced at $111.57 per ADS, corresponding to €95.34 per ordinary share based on the exchange rate of €1.00 = $1.1702 as published by the European Central Bank on April 30, 2026. This price reflects the volume-weighted average trading price of the ADSs on the Nasdaq Global Market over the five consecutive trading days ending May 1, 2026.
The 403,347 ordinary shares to be issued will result in dilution of approximately 0.5% of the company's share capital on a non-diluted basis. On an illustrative basis, a shareholder holding 1% of the company's share capital before the offering would hold a stake of 0.99% after completion.
Financial Position and Cash Runway
Abivax reported cash, cash equivalents, and short-term investments of €530.4 million as of December 31, 2025. Following the royalty certificate repurchase, the company's projected cash runway remains unchanged into the fourth quarter of 2027, indicating that the transaction is aimed at balance sheet optimization and financial flexibility rather than addressing near-term liquidity needs.
The repurchased royalty certificates will be immediately cancelled upon closing, which is expected on or about May 7, 2026. The new ordinary shares underlying the ADSs are expected to be admitted to trading on Euronext Paris and the ADSs on the Nasdaq Global Market around the same date.
Accounting and Advisory Details
The company will account for the repayment of the royalty certificates in accordance with applicable accounting standards, recognizing the transaction upon settlement and derecognizing the associated liability from its balance sheet. Any difference between the carrying value of the royalty certificates and the consideration paid will be recorded as a gain or loss in the company's results of operations for the quarter ending June 30, 2026.
Leerink Partners (搜索) acted as exclusive financial advisor to Abivax in connection with the offering, while Dechert (Paris) LLP and Cooley LLP served as legal advisors.
Strategic Implications for Obefazimod
Abivax's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis (搜索). By eliminating the royalty liability and maintaining its cash runway, the company strengthens its financial profile ahead of potential commercialization of obefazimod and signals a more streamlined, shareholder-friendly capital structure to investors in both Europe and the United States.
The company's shares trade on Euronext Paris and its ADSs are listed on the Nasdaq Global Market under the ticker "ABVX," providing dual-market access to European and U.S. investors.